EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

B-Soft Co Ltd (300451) fair value: what the stock is really worth

As of Sep 30, 2026: fair value of B-Soft Co Ltd ¥1.02, price ¥3.49, upside -70.8%, quality 36 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · CN · ISIN CNE100001ZG7

BS Thin data Oct 1, 2026

B-Soft Co Ltd

300451 · SHE

Weakest SetupStrongly overvalued and low quality.

Fair value ¥1.02 · Strongly overvalued (−70.8%)
Quality 36/100
Weak Growth (revenue 5y −8.4 %/yr in CNY)
Loss-making · -55.7% net margin (TTM)
Negative free cash flow
Trails peers (2/9)
Narrow moat 8/100
Thin data
Watch B-Soft Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥11.52 ¥3.10 Fair Value ¥1.02 Apr 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.

How to read this chart

60‑month range ¥3.10 – ¥11.52 · fair‑value band ¥0.6800 – ¥1.28 · the ¥3.49 price screens above the ¥1.02 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 1, 2026.

Follow B-Soft Co in your weekly email

Every Wednesday you see whether B-Soft Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

B-SOFT Co.,Ltd. operates in the healthcare information technology industry in China. The company offers Huikang·Yunshu Intelligent Body, a medical AI agent of Huikang.

Show more

B-SOFT Co.,Ltd. operates in the healthcare information technology industry in China. The company offers Huikang·Yunshu Intelligent Body, a medical AI agent of Huikang. It also provides outpatient registration and appointment center, medical technology appointment center, inpatient and outpatient services, and hospital cloud platform; and big data and artificial intelligence, hospital-wide medical-technical integration, mobile intelligent healthcare, hospital multidisciplinary consultation, clinical decision, b-soft overall solution for epidemic prevention and control, and Hi-HIS. In addition, the company offers management decision support, intelligent comprehensive management, hospital medical insurance risk management, performance management, intelligent management application, refined management system for low value consumables, consumables traceability management system, and consumables trading supervision and drug trade supervision platform; and intelligent IoT, multidisciplinary telemedicine, and 5G prehospital emergency. Further, it provides medical security information platform, DRG/DIP hospital side applications, and single disease quality management control; intelligent health; and city level health services platform and internet plus nursing services. B-SOFT Co.,Ltd. was founded in 1997 and is headquartered in Hangzhou, China.

Stock analysis

B-Soft Co Ltd (300451) currently trades at ¥3.49, while our model-based Fair Value estimate is ¥1.02, 70.8% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 93/100, which puts the evidence level at low.

Scenario range: ¥0.6800 (bear) to ¥1.28 (bull), the price of ¥3.49 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

B-Soft Co Ltd reported revenue of 1.1B CNY in FY2025 versus 1.9B CNY in FY2021, a compound −13.7%/yr. Reported net income was −402M CNY in FY2025.

Key figures

Market cap 5.4B CNY (≈ $806M) · P/S ratio 5.82 · EPS (TTM) ¥−0.3400 · Net margin −38.2% · Return on equity −12.4% · Return on assets (EBIT) 0.7% · Operating margin −53.8% · Revenue (TTM) 930M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 47% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at −71%, 300451 screens richer than that median.

Fair Value models

Bear ¥0.6800 Fair Value ¥1.02 Bull ¥1.28
Price ¥3.49 · Upside -70.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) ¥1.29 ¥1.73 ¥2.59 51
All 1 models by family
Asset-Based
NCAV (Graham) ¥1.29 ¥1.73 ¥2.59 51

Open the full fair value analysis →

Quality Score breakdown

Overall quality 36/100

Of which business quality 36 · Market factors (momentum, volatility) 31

Profitability 3
Margins and returns on capital today
Quality Growth 6
Are margins and returns improving?
Cashflow 3
Earnings quality: real cash, not paper profit
Fin. Strength 82
Balance sheet, leverage, solvency risk
Investment 73
Disciplined investing over empire-building
Low Volatility 74
Calm price path (market factor)
Momentum 17
Price trend over the last 3–12 months (market factor)
52W Momentum 5
Distance to the 52-week high (market factor)
Net Issuance 65
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−26.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−11.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.4%
Start year 2020 (pandemic). Over 10 years: +9.5% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.5%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
23.1% (2020) → −17.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

300451 screens overvalued: fair value 71% below the price. Compare with Veeva Systems Inc →

Compare B-Soft Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 116 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 36 · Bottom 25%
Fair Value upside −70.8% · Bottom 25%
Profitability
Return on assets −5.9% · Bottom 25%
Net margin (TTM) −55.7% · Bottom 25%
Operating margin (TTM) −53.8% · Bottom 25%
Growth and dividend
Revenue growth −10.1% · Bottom 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 0.20× · Cheapest 25%
P/S (TTM) 0.87× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $273.33 $300.66 +10%
Pro Medicus Limited PME A$161.00 A$84.62 −47%
BrightSpring Health Services, Inc BTSG $56.54 $25.86 −54%
Hinge Health, Inc HNGE $95.57 $51.25 −46%
HealthEquity, Inc HQY $88.44 $97.28 +10%
Waystar Holding WAY $24.70 $27.17 +10%
Doximity, Inc DOCS $27.93 $31.41 +12%
XtalPi Holdings 2228 HK$7.75 HK$1.50 −81%
Inventurus Knowledge Solutions Limited IKS ₹1,779 ₹1,883 +6%
Privia Health Group PRVA $19.62 $5.02 −74%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

B-Soft Co Ltd · Fair Value
¥1.02 −71%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "B-Soft Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300451

Frequently asked questions

Is B-Soft Co Ltd (300451) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of ¥1.02 versus the last price from Sep 30, 2026 of ¥3.49, about −71% upside (overvalued).
What is the fair value of 300451?
Our model-based fair value for B-Soft Co Ltd is ¥1.02 (as of Oct 1, 2026), built from audited fundamentals. Last price (from Sep 30, 2026): ¥3.49.
What is the quality score of 300451?
B-Soft Co Ltd has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for B-Soft Co Ltd (300451)?
Our model-based price target is the fair value of ¥1.02 (as of Oct 1, 2026) from 1 valuation models. Cautious scenario ¥0.6800, optimistic scenario ¥1.28. It is a calculation from audited fundamentals, not an analyst target.
What is the B-Soft Co Ltd stock forecast for 2026?
Our models put fair value at ¥1.02, about −71% upside versus the last price from Sep 30, 2026 of ¥3.49 (overvalued). Cautious scenario ¥0.6800, optimistic scenario ¥1.28. The calculation is refreshed regularly with new filings.
What is the revenue of B-Soft Co Ltd (300451)?
B-Soft Co Ltd reported trailing-twelve-month revenue of about 930M CNY (latest available figure, as of Oct 1, 2026).
What is the intrinsic value of B-Soft Co Ltd (300451)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For B-Soft Co Ltd it is ¥1.02 per share (as of Oct 1, 2026), against a price of ¥3.49. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is B-Soft Co Ltd stock overvalued or undervalued in 2026?
As of Oct 1, 2026, 300451 trades above its calculated fair value: price ¥3.49, fair value ¥1.02, a gap of about −71% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300451?
No. The price is what the market pays today (¥3.49); the fair value is what the company's own numbers justify (¥1.02). For B-Soft Co Ltd the two are ¥2.47 per share apart. That gap is exactly why we show both numbers side by side.
How much is B-Soft Co Ltd worth?
The market values B-Soft Co Ltd at about 5.4B CNY (market capitalisation, as of Oct 1, 2026). Per share that is ¥3.49; our models calculate a fair value of ¥1.02 per share.
What do the bullish and bearish scenarios say about 300451?
Our models span a range for B-Soft Co Ltd: cautious scenario ¥0.6800, base ¥1.02, optimistic ¥1.28 per share (as of Oct 1, 2026, price ¥3.49). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of B-Soft Co Ltd (300451)?
Balance-sheet figures for B-Soft Co Ltd (as of Oct 1, 2026): return on equity −12.4%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is 300451 from its 52-week high?
B-Soft Co Ltd trades at ¥3.49, about 47% below its 52-week high of ¥6.63 and 11% above the low of ¥3.14 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥1.02 is for.
Which stocks are comparable to B-Soft Co Ltd?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is B-Soft Co Ltd stock attractive at the current price?
The data as of Oct 1, 2026: price ¥3.49, calculated fair value ¥1.02 (−71%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300451 calculated?
We run B-Soft Co Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥1.02, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.4 % above its aggregate fair value. B-Soft Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of B-Soft Co Ltd (300451)?
The latest price we hold is from Sep 30, 2026 and stands at ¥3.49. Our model-based fair value is ¥1.02, about −71% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with B-Soft Co Ltd right now?
The price sits above even our optimistic bull case (¥1.28). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (¥0.6800 to ¥1.28) leaves room in how you read the outcome.
Where does the earnings growth of B-Soft Co Ltd (300451) come from?
Earnings per share at B-Soft Co Ltd grew −8.1 % a year from 2013 to 2024. Broken into its drivers: revenue per share +10.2 %, EBIT margin −9.3 %, tax rate +0.0 %, residual (interest, one-offs) −8.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of B-Soft Co Ltd

How large is the market capitalisation of B-Soft Co Ltd (300451)?
The market capitalisation of B-Soft Co Ltd is 5.4B CNY (≈ $806M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of B-Soft Co Ltd (300451)?
The price-to-sales ratio of B-Soft Co Ltd is 5.82 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of B-Soft Co Ltd (300451)?
Earnings per share at B-Soft Co Ltd are ¥−0.3400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of B-Soft Co Ltd (300451)?
The net margin of B-Soft Co Ltd is −38.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of B-Soft Co Ltd (300451)?
The return on equity (ROE) of B-Soft Co Ltd is −12.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of B-Soft Co Ltd (300451)?
On an EBIT basis the return on assets of B-Soft Co Ltd is 0.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of B-Soft Co Ltd (300451)?
The operating margin of B-Soft Co Ltd is −53.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at B-Soft Co Ltd (300451)?
Revenue at B-Soft Co Ltd is growing −10.1% versus a year earlier (3y avg −11.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at B-Soft Co Ltd (300451)?
Earnings per share at B-Soft Co Ltd are growing −67.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does B-Soft Co Ltd (300451) generate?
The free cash flow of B-Soft Co Ltd is −194M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does B-Soft Co Ltd (300451) hold?
B-Soft Co Ltd holds more cash than debt, 962M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch B-Soft Co Ltd in the live analysis

One click puts B-Soft Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.